Sintx Technologies Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Eric Olson

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	10yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Eric Olson (61 yo)

less than a year

Titularisation

US$585,423

Compensation

Mr. Eric K. Olson was Director and President of Amedica Spine of Sintx Technologies, Inc. Mr. Eric K. Olson is President, CEO & Director of Sintx Technologies, Inc. from 2024. Mr. Eric K. Olson serves as t...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Eric Olson	President	less than a year	US$585.42k	pas de données
David Truetzel	Independent Director	14.1yrs	US$124.21k	0% $ 0
Erik Stookey	Independent Director	10yrs	US$43.43k	0% $ 0
B. Bal	Chairman of the Board	12.7yrs	US$536.95k	0.00013% $ 3.2
Jeffrey White	Independent Director	10.8yrs	US$43.43k	pas de données
Mark Froimson	Independent Director	5.7yrs	US$43.18k	0% $ 0
Giuseppe Pezzotti	Member of Scientific Advisory Board	9.1yrs	pas de données	pas de données

10.0yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la 0A8S est chevronné et expérimenté ( 10 années d'ancienneté moyenne).

Sintx Technologies Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

Insufficient new directors

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Recent updates

Sintx Technologies, Inc. Announces Key Executive Promotions: Ryan Bock, Phd, Named Chief Technology Officer and Ann Kutsch Promoted to President of Sintx Ta&T

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Second quarter 2024 earnings released: US$3.49 loss per share (vs US$122 loss in 2Q 2023)

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

New major risk - Financial position

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Insufficient new directors

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Insufficient new directors

Insufficient new directors

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Insufficient new directors

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen